Medifocus Inc.

Medifocus Inc.

June 28, 2011 10:32 ET

Medifocus Inc. Announces Units Offering

TORONTO, ONTARIO--(Marketwire - June 28, 2011) -


Medifocus Inc. ("Medifocus" or the "Company") (TSX VENTURE:MFS)(PINK SHEETS:MDFZF) announces, subject to regulatory approval, an arm's length non-brokered private placement of 1,000,000 units (the "Units") at a price of $0.30 per Unit for gross proceeds of $300,000. Each Unit is comprised of one Common Share and one-half Series A Common Share purchase warrant. Each whole Series A Common Share purchase warrant will entitle the holder to purchase one additional Medifocus Common Share at a price of $0.45 for a period of 18 months following the completion of the offering.

The net proceeds of this offering will be primarily used by Medifocus to initiate a pivotal phase III clinical trial using Medifocus Microfocus APA 1000 System for the treatment of breast cancer (including all related professional expenses) and for working capital.

Medifocus owns a patented microwave focusing technology platform (the Adaptive Phased Array ("APA") technology), which can precisely target and control microwave energy to cause heating in cancerous tumors anywhere in the body reliably and repeatedly. The ability to target tumors with a precision controlled dose of heat can be used to destroy tumors at higher temperatures, to treat tumors in combination with chemotherapy and/or radiation at moderate temperatures for increased effectiveness and reduced toxicity and to trigger the targeted release of therapeutic drugs and genes at tumor sites at lower temperatures. While the core technology has been licensed from the Massachusetts Institute of Technology, Medifocus has further refined the precision of the microwave focusing and control ability and developed a commercial system dedicated exclusively for the treatment of Breast Cancer. Please visit for more details.

Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) has in any way passed upon the merits of the proposed transactions and neither of the foregoing entities has approved or disapproved of the contents of this press release.

Contact Information